TITLE

Management of Severely Immunocompromised Human Immunodeficiency Virus Type 1--Infected African Orphans with Structured Treatment Interruption: Another Kind of Salvage Therapy

AUTHOR(S)
Chakraborty, Rana; Musoke, Rachel; Palakudy, Tresa; Cross, Alexandra; D'Agostino, Angelo
PUB. DATE
June 2003
SOURCE
Clinical Infectious Diseases;6/1/2003, Vol. 36 Issue 11, p1483
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Without an effective therapeutic human immunodeficiency virus (HIV)-1 vaccine, providing cost-effective, minimally toxic antiretroviral therapy to the many individuals already infected with HIV-1 is a global priority. Implementation of a structured treatment interruption (STI) regimen may be a promising intervention for HIV-1 infection. We adopted this approach out of necessity for 3 severely immunocompromised African children naive to therapy, and increases in the T lymphocyte count and improved quality and sustainability of life 2 years after initiation of the STI regimen were noted.
ACCESSION #
10029955

 

Related Articles

  • Viral envelope fails to deliver? Bolognesi, Dani P.; Matthews, Thomas J. // Nature;2/12/1998, Vol. 391 Issue 6668, p638 

    Discusses research which analyzed the failure of two HIV vaccines. National Institutes of Health (NIH) clinical trials of two HIV vaccines; Struggle to establish standards for vaccine; Research by Connor et al in `Journal of Virology'; Use of recombinant gp120 subunit vaccines; Why vaccines...

  • Efficacy Testing of Recombinant Human Immunodeficiency Virus (HIV) gp160 as a Therapeutic Vaccine... Birx, Deborah L.; Loomis-Price, Lawrence D.; Aronson, Naomi; Brundage, John; Davis, Charles; Deyton, Lawrence; Garner, Robin; Gordin, Fred; Henry, David; Holloway, William; Kerkering, Thomas; Luskin-Hawk, Roberta; McNeil, John; Michael, Nelson; Pierce, Phillip Foster; Poretz, Donald; Ratto-Kim, Silvia; Renzullo, Phil; Ruiz, Nancy // Journal of Infectious Diseases;3/1/2000, Vol. 181 Issue 3, p881 

    Studies the effectiveness of recombinant HIV gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. Viral load measurements; Safety and tolerability of the vaccine; Cellular and humoral immunogenicities of the vaccine.

  • Back to basics.  // Nature Medicine;Aug2009, Vol. 15 Issue 8, p821 

    The article discusses various reports published within the issue including the basic HIV research advances and its renewed focus on HIV pathogenesis in HIV vaccine research, the result of "Nature Medicine's" project that identifies some key barriers to translational research in the field of HIV...

  • HEALTH: CLUES FROM SLEEPING SICKNESS. Fain, Nathan // Advocate;1/8/85, Issue 411, p14 

    Presents the author's views on the test of various drugs in treating AIDS disease. Experiment of a drug called suramin in the treatment of the disease; Widespread prevalence of AIDS in Zaire; AIDS infection among gay men; Assessment of various research works on AIDS therapy.

  • Vaccination in HIV-Infected Adults. Crum-Cianflone, Nancy F.; Wallace, Mark R. // AIDS Patient Care & STDs;Aug2014, Vol. 28 Issue 8, p397 

    Vaccines are critical components for protecting HIV-infected adults from an increasing number of preventable diseases. However, missed opportunities for vaccination among HIV-infected persons persist, likely due to concerns regarding the safety and efficacy of vaccines, as well as the changing...

  • Prevalence of HIV and Disease Outcomes on the Medical and Surgical Wards at Kamuzu Central Hospital, Lilongwe, Malawi. Kendig, Claire E.; McCulloch, Denise J.; Rosenberg, Nora E.; Samuel, Jonathan C.; Mabedi, Charles; Shores, Carol G.; Hosseinipour, Mina C.; Matoga, Mitch; Charles, Anthony G. // Tropical Medicine & Health;2013, Vol. 41 Issue 4, p163 

    Introduction: (WHO) recommends HIV Counseling and Testing (HCT) in a range of clinical settings. We describe the characteristics of patients diagnosed with HIV on the medical and surgical wards at a tertiary care hospital in Malawi. Methods: Under the universal opt-out HCT protocol we...

  • Capacity of Broadly Neutralizing Antibodies to Inhibit HIV-1 Cell-Cell Transmission Is Strain- and Epitope-Dependent. Reh, Lucia; Magnus, Carsten; Schanz, Merle; Weber, Jacqueline; Uhr, Therese; Rusert, Peter; Trkola, Alexandra // PLoS Pathogens;7/9/2015, Vol. 11 Issue 7, p1 

    An increasing number of broadly neutralizing antibodies (bnAbs) are considered leads for HIV-1 vaccine development and novel therapeutics. Here, we systematically explored the capacity of bnAbs to neutralize HIV-1 prior to and post-CD4 engagement and to block HIV-1 cell-cell transmission....

  • CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Kiepiela, Photini; Ngumbela, Kholiswa; Thobakgale, Christina; Ramduth, Dhanwanthie; Honeyborne, Isobella; Moodley, Eshia; Reddy, Shabashini; de Pierres, Chantal; Mncube, Zenele; Mkhwanazi, Nompumelelo; Bishop, Karen; van der Stok, Mary; Nair, Kriebashnie; Khan, Nasreen; Crawford, Hayley; Payne, Rebecca; Leslie, Alasdair; Prado, Julia; Prendergast, Andrew; Frater, John // Nature Medicine;Jan2007, Vol. 13 Issue 1, p46 

    Selection of T-cell vaccine antigens for chronic persistent viral infections has been largely empirical. To define the relationship, at the population level, between the specificity of the cellular immune response and viral control for a relevant human pathogen, we performed a comprehensive...

  • Bacterial AIDS vaccine ready for testing. Smaglik, Paul // Nature;5/25/2000, Vol. 405 Issue 6785, p386 

    Reveals plans as of May 2000 to test an AIDS vaccine which can be administered orally. Development at the Institute of Human Virology in Baltimore, Maryland, by George Lewis, director of the vaccine division; Tests to be given in Baltimore and Uganda; How Salmonella plays a part in boosting the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics